Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more
Theratechnologies Inc. (THTX) - Net Assets
Latest net assets as of May 2025: $-27.92 Million USD
Based on the latest financial reports, Theratechnologies Inc. (THTX) has net assets worth $-27.92 Million USD as of May 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($51.27 Million) and total liabilities ($79.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-27.92 Million |
| % of Total Assets | -54.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -883.87% |
| 10-Year Change | -268.75% |
| Growth Volatility | 111.06 |
Theratechnologies Inc. - Net Assets Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Theratechnologies Inc. (1996–2024)
The table below shows the annual net assets of Theratechnologies Inc. from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $-25.27 Million | -21.09% |
| 2023-11-30 | $-20.87 Million | +7.54% |
| 2022-11-30 | $-22.57 Million | -227.09% |
| 2021-11-30 | $17.76 Million | +450.87% |
| 2020-11-30 | $3.22 Million | -87.02% |
| 2019-11-30 | $24.83 Million | -29.08% |
| 2018-11-30 | $35.02 Million | +4.51% |
| 2017-11-30 | $33.51 Million | +67.42% |
| 2016-11-30 | $20.02 Million | +33.65% |
| 2015-11-30 | $14.98 Million | +118.02% |
| 2014-11-30 | $6.87 Million | -60.64% |
| 2013-11-30 | $17.45 Million | -23.53% |
| 2012-11-30 | $22.82 Million | -35.16% |
| 2011-11-30 | $35.20 Million | -31.85% |
| 2010-11-30 | $51.65 Million | +26.90% |
| 2009-11-30 | $40.70 Million | +7.67% |
| 2008-11-30 | $37.80 Million | -42.68% |
| 2007-11-30 | $65.94 Million | +69.25% |
| 2006-11-30 | $38.96 Million | -7.14% |
| 2005-11-30 | $41.96 Million | -20.86% |
| 2004-11-30 | $53.02 Million | -17.78% |
| 2003-11-30 | $64.48 Million | -18.90% |
| 2002-11-30 | $79.51 Million | +12.07% |
| 2001-11-30 | $70.95 Million | +84.12% |
| 2000-11-30 | $38.53 Million | +127.88% |
| 1999-11-30 | $16.91 Million | +54.60% |
| 1998-11-30 | $10.94 Million | +55.64% |
| 1997-11-30 | $7.03 Million | -40.44% |
| 1996-11-30 | $11.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theratechnologies Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40508737106.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $363.93 Million | % |
| Other Comprehensive Income | $898.00K | % |
| Other Components | $26.79 Million | % |
| Total Equity | $-25.27 Million | 100.00% |
Theratechnologies Inc. Competitors by Market Cap
The table below lists competitors of Theratechnologies Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hangzhou Gisway Information Technology Co. Ltd. A
SHE:301390
|
$129.65 Million |
|
AKATSUKI INC.
F:7QT
|
$129.66 Million |
|
Jeju Air Co Ltd
KO:089590
|
$129.67 Million |
|
Gongwin Biopharm Holdings Co. Ltd.
TWO:6617
|
$129.68 Million |
|
EKF Diagnostics Holdings plc
PINK:EKDHF
|
$129.58 Million |
|
Hansa Biopharma AB
ST:HNSA
|
$129.55 Million |
|
Wuxi Xinan Technology Co. Ltd. A
SHE:301170
|
$129.48 Million |
|
Zentalis Pharmaceuticals Llc
NASDAQ:ZNTL
|
$129.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theratechnologies Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -20,870,000 to -25,272,000, a change of -4,402,000.
- Net loss of 8,306,000 reduced equity.
- Other comprehensive income increased equity by 214,000.
- Other factors increased equity by 3,690,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.31 Million | -32.87% |
| Other Comprehensive Income | $214.00K | +0.85% |
| Other Changes | $3.69 Million | +14.6% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Theratechnologies Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-11-30 | $0.80 | $3.39 | x |
| 1997-11-30 | $0.42 | $3.39 | x |
| 1998-11-30 | $0.60 | $3.39 | x |
| 1999-11-30 | $0.83 | $3.39 | x |
| 2000-11-30 | $1.43 | $3.39 | x |
| 2001-11-30 | $1.97 | $3.39 | x |
| 2002-11-30 | $2.15 | $3.39 | x |
| 2003-11-30 | $1.76 | $3.39 | x |
| 2004-11-30 | $1.49 | $3.39 | x |
| 2005-11-30 | $1.17 | $3.39 | x |
| 2006-11-30 | $0.90 | $3.39 | x |
| 2007-11-30 | $1.25 | $3.39 | x |
| 2008-11-30 | $0.66 | $3.39 | x |
| 2009-11-30 | $0.67 | $3.39 | x |
| 2010-11-30 | $0.84 | $3.39 | x |
| 2011-11-30 | $0.58 | $3.39 | x |
| 2012-11-30 | $0.37 | $3.39 | x |
| 2013-11-30 | $0.29 | $3.39 | x |
| 2014-11-30 | $0.11 | $3.39 | x |
| 2015-11-30 | $0.24 | $3.39 | x |
| 2016-11-30 | $0.30 | $3.39 | x |
| 2017-11-30 | $0.46 | $3.39 | x |
| 2018-11-30 | $1.84 | $3.39 | x |
| 2019-11-30 | $1.29 | $3.39 | x |
| 2020-11-30 | $0.04 | $3.39 | x |
| 2021-11-30 | $0.19 | $3.39 | x |
| 2022-11-30 | $-0.24 | $3.39 | x |
| 2023-11-30 | $-0.29 | $3.39 | x |
| 2024-11-30 | $-0.51 | $3.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theratechnologies Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.67%
- • Asset Turnover: 1.61x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-58.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -29.56% | -940.00% | 0.02x | 1.38x | $-4.67 Million |
| 1997 | -57.00% | -1425.00% | 0.03x | 1.21x | $-4.71 Million |
| 1998 | -30.36% | -463.64% | 0.06x | 1.14x | $-4.41 Million |
| 1999 | -19.68% | -326.67% | 0.06x | 1.09x | $-5.02 Million |
| 2000 | 9.79% | 470.29% | 0.01x | 1.43x | $-79.46K |
| 2001 | 30.31% | 593.71% | 0.03x | 1.61x | $11.38 Million |
| 2002 | -13.97% | -167.26% | 0.06x | 1.37x | $-15.72 Million |
| 2003 | -46.53% | -818.02% | 0.04x | 1.34x | $-30.67 Million |
| 2004 | -36.24% | -861.31% | 0.04x | 1.08x | $-24.52 Million |
| 2005 | -29.27% | -87.13% | 0.31x | 1.09x | $-16.48 Million |
| 2006 | -58.15% | -1568.28% | 0.03x | 1.15x | $-26.55 Million |
| 2007 | -56.97% | -1199.36% | 0.04x | 1.13x | $-44.16 Million |
| 2008 | -104.28% | -1853.58% | 0.05x | 1.15x | $-43.20 Million |
| 2009 | -34.98% | -86.20% | 0.25x | 1.61x | $-18.31 Million |
| 2010 | 16.96% | 28.02% | 0.44x | 1.36x | $3.59 Million |
| 2011 | -48.79% | -118.77% | 0.28x | 1.45x | $-20.69 Million |
| 2012 | -61.49% | -102.75% | 0.37x | 1.60x | $-16.32 Million |
| 2013 | -21.89% | -53.69% | 0.30x | 1.34x | $-5.56 Million |
| 2014 | -133.97% | -156.58% | 0.21x | 4.15x | $-9.89 Million |
| 2015 | 7.85% | 5.23% | 0.60x | 2.50x | $-322.64K |
| 2016 | 1.52% | 1.11% | 0.70x | 1.97x | $-1.70 Million |
| 2017 | -42.79% | -43.04% | 0.56x | 1.77x | $-17.69 Million |
| 2018 | -13.42% | -10.66% | 0.40x | 3.17x | $-8.20 Million |
| 2019 | -50.32% | -19.77% | 0.54x | 4.73x | $-14.98 Million |
| 2020 | -703.07% | -34.32% | 0.66x | 31.06x | $-22.99 Million |
| 2021 | -178.63% | -45.44% | 0.59x | 6.71x | $-33.50 Million |
| 2022 | 0.00% | -59.00% | 0.86x | 0.00x | $-44.98 Million |
| 2023 | 0.00% | -29.30% | 1.05x | 0.00x | $-21.87 Million |
| 2024 | 0.00% | -9.67% | 1.61x | 0.00x | $-5.78 Million |
Industry Comparison
This section compares Theratechnologies Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theratechnologies Inc. (THTX) | $-27.92 Million | -29.56% | N/A | $129.60 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |